ESPE Abstracts (2023) 97 P1-155

ESPE2023 Poster Category 1 Pituitary, Neuroendocrinology and Puberty (73 abstracts)

The long-term efficacy of triptorelin 3-month depot in girls with central precocious puberty

Kyu Hyun Park 1 , Si-Hwa Gwag 1 , Lindsey Yoojin Chung 2 , Eungu Kang 1 , Hyo-Kyoung Nam 1 , Young-Jun Rhie 1 & Kee-Hyoung Lee 1


1Korea University College of Medicine, Seoul, Korea, Republic of. 2Myongji Hospital, Gyeonggi-do, Korea, Republic of


Purpose: The 3-month gonadotropin-releasing hormone analogs (GnRHa) are expected to achieve better compliance in central precocious puberty (CPP) patients, but the 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of 3-month GnRHa for the treatment of CPP.

Methods: In this retrospective study, 69 Korean girls diagnosed with CPP were included with either the triptorelin pamoate (TP) 3-month (n= 29) or triptorelin acetate (TA) 1-month (n= 40) GnRHa and were followed up to one year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.

Results: The baseline characteristics of the subjects were similar between the two groups. The 28/29 (96.6%) of patients in the 3-month TP group had suppressed LH levels (below 2.5IU/L) after 12[W사1] months of treatment, and this suppression level was[W사2] reserved until the final injection. The degree of bone age (BA) advancement in the 3-month TP group decreased from 1.8 ± 0.4 years at the start of treatment to 0.6 ± 0.5 years one-year post-treatment. The height gain in predicted adult height (PAH) at one year after the end of treatment was[W사3] similar between the 3-month and 1-month groups, with a gain of 5.2 ± 3.1 and 5.3 ± 2.4 cm, respectively (P= 0.875)

Conclusion: Our long-term follow-up study showed that the 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. We suggest that considering convenience of patients, 3-month GnRHa is promising as a CPP treatment option.

Volume 97

61st Annual ESPE (ESPE 2023)

The Hague, Netherlands
21 Sep 2023 - 23 Sep 2023

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.